How We’re Mobilizing Our Resources to Help Find Solutions for Covid-19
Learn More
Share
Office of the Chief Medical Officer
he Johnson & Johnson Office of the Chief Medical Officer is a global group of medical and scientific professionals focused on advancing evidence- and science-based decision-making that is driven by bioethical principles and values.
Our Ethics- and Science-Driven Healthcare Initiatives
Within Johnson & Johnson’s Office of the Chief Medical Officer, safety assessment that is objective and science- and evidence-based is at the core of what we do and is built into every stage of our products’ life cycles—from development to post-launch. But just how do we do it?
The Office of the Chief Medical Officer believes in the collective power of real-world observational data to complement clinical trial findings, and in sharing our insights to improve health outcomes.
At Johnson & Johnson, we invest billions of dollars every year in research and development that leads to breakthrough therapies and scientific knowledge to advance medicine. When we share clinical trial data and results, we help expand the understanding of diseases, which can shape new treatments.
Bioethics is an applied discipline that takes the principles of ethics and applies them to biological research, science and medicine. Adherence to bioethical principles—including transparency, integrity and respect for the rights and welfare of all persons—stems from Our Credo values and the commitment we make to our patients and consumers.
Caring for children and their health has been a mainstay of Johnson & Johnson’s 130-year history.
Featured
Every day, we work to put people first—from proactive and transparent medical safety surveillance, to groundbreaking real-world evidence applications, pediatric clinical research advancements, early access innovation and more.
For Baby Safety Month, we sat down with the company's Head of Pediatric Drug Development to learn about its industry-leading Child Health Innovation Leadership Department.
A Q&A with Gary Eichenbaum, Ph.D., Vice President, Preclinical Science and Safety, Office of the Chief Medical Officer, Johnson & Johnson.
The company's mission is to care for the world—one person at a time. Just ask Chief Medical Officer Joanne Waldstreicher, M.D., who's been leading the charge to improve the process by which very sick patients may apply for access to investigational medications.
Johnson & Johnson Chief Medical Officers
Our Chief Medical Officers drive medical safety excellence and innovation across our Pharmaceuticals, Medical Devices and Consumer Products sectors.
In the News
News and highlights about the Office of the Chief Medical Officer.
Scientific Policies
Johnson & Johnson is committed to ethical decision-making and transparency to guide every decision we make. Read more for our scientific policies on sensitive topics.
-
November 09, 2016These guidelines are to ensure that human pluripotent stem cell research conducted by Johnson & Johnson conforms to current international standards of scientific and ethical oversight, and that all scientists and employees of the Johnson & Johnson Family of Companies adhere to these ethical principles when conducting human pluripotent stem cell research.
November 09, 2016Our Ethical Code for the Conduct of Research and Development is intended to complement our Credo by providing more specific standards of conduct and behavior for physicians, clinical research scientists and others who are responsible for medical aspects of research and development.
November 09, 2016We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.
November 09, 2016We follow five important principles when providing pre-approval access to investigational medicines to patients with serious diseases to access medicines not yet approved by regulatory health authorities.More From Johnson & Johnson
Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
